Stay updated with breaking news from Jessie hanrahan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Solid Biosciences Inc. (NASDAQ:SLDB – Get Free Report) insider Jessie Hanrahan sold 4,879 shares of Solid Biosciences stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $2.78, for a total value of $13,563.62. Following the transaction, the insider now owns 6,983 shares of the company’s […] ....
Project Orbis has worked very well for oncology products. CBER Director Dr. Peter Marks has recently started promoting the development of a similar. ....
30.09.2022 - - Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo - - Strong synergies expected by combining key assets, including . ....
Novartis has lost another NIBR exec to the call of biotech. Blueprint Medicines has added another BMS vet to its roster. And Iovance quietly announced its CEO's departure Wednesday. ....
Published: May 21, 2021 By Alex Keown Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers. AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she worked across the oncology, multiple sclerosis and rare disease therapeutic areas. Earlier in her career, Hanrahan worked at Boston Scientific Corporation. ....